Royalty Pharma
2025–2026 federal contribution records · FEC Schedule A
01
Contribution summary
Loading the financial summary…
Reading the shared contribution publication for this cycle.
2025–2026 federal contribution records · FEC Schedule A
Loading the financial summary…
Reading the shared contribution publication for this cycle.
Federal contribution records grouped across normalized variants of this reported employer. Contributions are made by individuals, not by the employer.
Current-version rows · memo entries excluded from net amount
Last updated . These are the last published financial totals; newer source data is not included yet.
A current recipient-party breakdown has not been published. Financial totals remain available; older party percentages are not shown.
Loading 10 contributions with dates…
Loading company overview…
These immutable labels appeared in FEC filings and are grouped under Royalty Pharma.
Showing the last published contribution snapshot. Newer source data is not included yet.
Top 10 contributors and top 10 recipients · independent of list pagination
Explore the reported connections for Royalty Pharma. Contributor and recipient lists are available below.
Data: GovMoneyGraph, based on FEC records. Groupings and recipient-party allocations are derived analysis, not FEC-verified identities or party registrations. Read our contribution and classification methodology.
Reported contributor groups, with evidence-based name-variant matching; not verified unique people · 10 per page
Showing 1–2 of 2 · largest absolute amount first
Reported name + ZIP cluster; not a verified identity merge · NEW YORK, NY, 10007 · ROYALTY PHARMA · Finance, Insurance & Real Estate · DIRECTOR · 16 transaction rows
Reported name + ZIP cluster; not a verified identity merge · MANHATTAN, NY, 10023 · ROYALTY PHARMA · Finance, Insurance & Real Estate · BUSINESS · 2 transaction rows
Where the contributions went · 10 per page
Showing 1–7 of 7 · largest absolute amount first
PAC (not qualified) · FOXBORO, MA · 4 transaction rows
House campaign committee · NEW YORK, NY · GOLDMAN, DANIEL · U.S. House NY 10 · 4 transaction rows
Party committee (qualified) · TRENTON, NJ · 2 transaction rows
House campaign committee · NEW YORK, NY · LASHER, MICAH CHARLES · U.S. House NY 12 · 2 transaction rows
Senate campaign committee · ROYAL OAK, MI · MCMORROW, MALLORY · U.S. Senate MI 00 · 2 transaction rows
House campaign committee · SMITHTOWN, NY · GALLANT, CHRISTOPHER · U.S. House NY 01 · 2 transaction rows
PAC with non-contribution account · BOSTON, MA · 2 transaction rows
Individual transactions · 10 per page
Dates below are the FEC-reported contribution dates, not filing or import dates. These are individual contributions grouped by the reported employer field, not contributions by a company.
Showing the last published contribution records; newer source data is not included yet.
Largest contribution amounts first. Select Date of contribution or Amount to reverse the order.
| Date of contribution ↕ | Amount ↓ | Reported contributor / location | Recipient / filing |
|---|---|---|---|
| 2025-12-19FEC filing ↗ | $2,000 | TILAK, GAURIENEW YORKNY10023BUSINESSROYALTY PHARMA | LASHER FOR CONGRESSC00918565Primary 2026 (P2026)* EARMARKED CONTRIBUTION: SEE BELOWFiling 1992985 · amended |
| 2025-11-17FEC filing ↗ | $1,500Memo only · not additional money | URIST, MARSHALLNEW YORKNY10007DIRECTOR RESEARCH AND INVESTMENTSROYALTY PHARMA | DAN GOLDMAN FOR NEW YORKC00816660General 2026 (G2026)* REDESIGNATED FROM PRIMARY 2026Filing 1943623 |
| 2025-08-05FEC filing ↗ | $1,450 | URIST, MARSHALLNEW YORKNY10007BIOTECHNOLOGYROYALTY PHARMA | GALLANT FOR CONGRESSC00914770Primary 2026 (P2026)* EARMARKED CONTRIBUTION: SEE BELOWFiling 1920295 |
| 2025-08-05FEC filing ↗ | $1,450 | URIST, MARSHALLMANHATTANNY10007BIOTECHNOLOGYROYALTY PHARMA | ACTBLUEC00401224Not reportedEARMARKED FOR GALLANT FOR CONGRESS (C00914770)Filing 1953256 · amended |
| 2026-01-30FEC filing ↗ | $1,000 | URIST, MARSHALLNEW YORKNY10007BIOTECHNOLOGYROYALTY PHARMA | MCMORROW FOR MICHIGANC00901173Primary 2026 (P2026)Filing 1966642 |
| 2025-11-16FEC filing ↗ | $500 | URIST, MARSHALLMANHATTANNY10007BIOTECHNOLOGYROYALTY PHARMA | ACTBLUEC00401224Not reportedCONTRIBUTION TO ACTBLUEFiling 1953256 · amended |
| 2025-08-05FEC filing ↗ | $145 | URIST, MARSHALLMANHATTANNY10007BIOTECHNOLOGYROYALTY PHARMA | ACTBLUEC00401224Not reportedCONTRIBUTION TO ACTBLUEFiling 1953256 · amended |
| 2025-11-17FEC filing ↗ | -$1,500Memo only · not additional money | URIST, MARSHALLNEW YORKNY10007DIRECTOR RESEARCH AND INVESTMENTSROYALTY PHARMA | DAN GOLDMAN FOR NEW YORKC00816660Primary 2026 (P2026)* REDESIGNATED TO GENERAL 2026Filing 1943623 |
Refunds remain negative. Memo-only rows are marked and are not additional money. Rows come from the latest available contribution publication.
Open full contribution table →Industry classification summary
Royalty Pharma is identified as a specialty biopharmaceutical finance company that acquires royalty interests and provides funding to the industry. While it supports the pharmaceutical sector, its primary business model is investment and specialty finance, placing it in the Finance sector.
AI classification auto-approved under admin authorization
View source